Clinical Trial Update: Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate [Phase 1]

View source ↗

Summary

Phase 1 single-dose pharmacokinetic study in subjects with severe Hemophilia A comparing BAY81-8973 and Advate has completed. The trial evaluated PK parameters …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ADVATE (antihemophilic factor VIII)
• BAY81-8973 (recombinant coagulation factor VIII)

Snippet

Sponsor: Bayer | Conditions: Hemophilia A | Phase 1 | Status: COMPLETED